| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | P2RY14 |
| Uniprot No | Q15391 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-338aa |
| 氨基酸序列 | MINSTSTQPPDESCSQNLLITQQIIPVLYCMVFIAGILLNGVSGWIFFYVPSSKSFIIYLKNIVIADFVMSLTFPFKILGDSGLGPWQLNVFVCRVSAVLFYVNMYVSIVFFGLISFDRYYKIVKPLWTSFIQSVSYSKLLSVIVWMLMLLLAVPNIILTNQSVREVTQIKCIELKSELGRKWHKASNYIFVAIFWIVFLLLIVFYTAITKKIFKSHLKSSRNSTSVKKKSSRNIFSIVFVFFVCFVPYHIARIPYTKSQTEAHYSCQSKEILRYMKEFTLLLSAANVCLDPIIYFFLCQPFREILCKKLHIPLKAQNDLDISRIKRGNTTLESTDTL |
| 预测分子量 | 38,9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于P2RY14重组蛋白的3篇参考文献(注：文献信息为示例性内容，具体文献需通过学术数据库核实)：
---
1. **文献名称**: *"Characterization of the human P2RY14 receptor: Expression and functional analysis in immune cells"*
**作者**: Barrett MO, et al.
**摘要**: 本研究利用重组P2RY14蛋白在HEK293细胞中表达，证实其通过抑制cAMP信号通路响应尿苷二磷酸葡萄糖(UDP-glucose)激活，揭示了其在单核细胞和树突状细胞中的免疫调节作用。
2. **文献名称**: *"Structural insights into P2RY14 activation by nucleotide-sugar ligands"*
**作者**: Köse M, et al.
**摘要**: 通过冷冻电镜解析重组人源P2RY14与配体UDP-galactose结合的复合物结构，阐明其配体结合口袋的关键氨基酸残基，为靶向该受体的药物设计提供结构基础。
3. **文献名称**: *"Development of a high-throughput screening assay for P2RY14 antagonists using recombinant receptor technology"*
**作者**: Fricks DJ, et al.
**摘要**: 构建稳定表达P2RY14重组蛋白的CHO细胞系，开发基于钙流检测的抑制剂筛选平台，鉴定出多个新型拮抗剂，推动炎症性疾病治疗药物的研发。
---
**备注**：建议通过PubMed或Web of Science检索实际文献(关键词：P2RY14 recombinant, expression, antagonist)，以获取最新研究进展。
P2RY14. a member of the P2Y receptor family, is a G protein-coupled receptor (GPCR) activated by extracellular nucleotide sugars like uridine diphosphate glucose (UDP-glucose). It plays roles in immune regulation, inflammation, and metabolic disorders, with emerging links to cancer. As a purinergic receptor, P2RY14 couples primarily to Gαi/o proteins, modulating intracellular signaling pathways such as cAMP inhibition, calcium mobilization, and MAP kinase activation. Its expression in immune cells, adipose tissue, and the central nervous system highlights diverse physiological and pathological functions.
Recombinant P2RY14 protein is engineered for in vitro studies to elucidate receptor-ligand interactions, signaling mechanisms, and therapeutic targeting. Produced via heterologous expression systems (e.g., HEK293 cells), it retains post-translational modifications critical for ligand binding and activity. Purification methods like affinity chromatography ensure high purity and stability. This recombinant tool enables drug discovery efforts, particularly for inflammatory diseases (e.g., asthma, diabetes) and cancers where P2RY14 overexpression correlates with progression. Researchers also use it to develop selective antagonists or antibodies, addressing challenges in receptor specificity due to structural similarities within the P2Y family. Current studies focus on its role in metabolic dysregulation, neuroinflammation, and crosstalk with other GPCRs, underscoring its potential as a biomarker or therapeutic target.
×
